Sleep apnea or other forms of the sleep disorder require an effective CPAP machine to enhance your health and sleep patterns.

There are many consequences of untreated OSA, and all of these are more likely with more-severe obstruction. Because people ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Would you please address the dangers of untreated sleep apnea? Also, what do people do when they are unable to tolerate a CPAP (continuous positive airway pressure) machine?

Here's why brokers are feeling bullish about these three shares this week. The post Brokers name 3 ASX shares to buy today ...